Pacific Biosciences of California, Inc. (PACB) stock
PACBNasdaqLaboratory Analytical InstrumentsFiscal year ends December 31
$1.96−0.01 (-0.51%)
Close on Nov 13, 2026Market cap $609.23MP/E –Yield 0.00%
Pacific Biosciences of California r&d expenses
Research and development expenses are spending on new products and technology.
Pacific Biosciences of California's R&D Expenses for the twelve months ending Sep 30, 2026 was $85.73M, down 15.9% year over year. For fiscal 2025 it was $97.31M, down 27.9% from the year before. Over ten years it grew 4.9% a year on average. The highest annual figure on record is $193.00M in fiscal 2022.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $97.31M | -27.9% |
| FY2024 | Dec 31, 2024 | $134.92M | -27.9% |
| FY2023 | Dec 31, 2023 | $187.17M | -3.0% |
| FY2022 | Dec 31, 2022 | $193.00M | +70.9% |
| FY2021 | Dec 31, 2021 | $112.90M | +76.0% |
| FY2020 | Dec 31, 2020 | $64.15M | +7.6% |
| FY2019 | Dec 31, 2019 | $59.63M | -4.7% |
| FY2018 | Dec 31, 2018 | $62.59M | -4.2% |
| FY2017 | Dec 31, 2017 | $65.32M | -3.4% |
| FY2016 | Dec 31, 2016 | $67.62M | +11.9% |
| FY2015 | Dec 31, 2015 | $60.44M | +25.3% |
| FY2014 | Dec 31, 2014 | $48.23M | +6.7% |
| FY2013 | Dec 31, 2013 | $45.22M | -5.1% |
| FY2012 | Dec 31, 2012 | $47.62M | -37.4% |
| FY2011 | Dec 31, 2011 | $76.08M | -32.0% |
| FY2010 | Dec 31, 2010 | $111.82M | +47.4% |
| FY2009 | Dec 31, 2009 | $75.88M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $20.22M | -11.5% |
| Q2 FY2026 | Jun 30, 2026 | $23.02M | +2.2% |
| Q1 FY2026 | Mar 31, 2026 | $19.61M | -32.5% |
| Q4 FY2025 | Dec 31, 2025 | $22.88M | -16.7% |
| Q3 FY2025 | Sep 30, 2025 | $22.85M | -10.5% |
| Q2 FY2025 | Jun 30, 2025 | $22.53M | -41.5% |
| Q1 FY2025 | Mar 31, 2025 | $29.05M | -33.1% |
| Q4 FY2024 | Dec 31, 2024 | $27.47M | -38.3% |
| Q3 FY2024 | Sep 30, 2024 | $25.52M | -46.3% |
| Q2 FY2024 | Jun 30, 2024 | $38.49M | -16.7% |
| Q1 FY2024 | Mar 31, 2024 | $43.46M | -11.2% |
| Q4 FY2023 | Dec 31, 2023 | $44.54M | +4.5% |
| Q3 FY2023 | Sep 30, 2023 | $47.51M | +0.9% |
| Q2 FY2023 | Jun 30, 2023 | $46.17M | -8.3% |
| Q1 FY2023 | Mar 31, 2023 | $48.94M | -7.6% |
| Q4 FY2022 | Dec 31, 2022 | $42.62M | +0.1% |
| Q3 FY2022 | Sep 30, 2022 | $47.09M | +71.2% |
| Q2 FY2022 | Jun 30, 2022 | $50.35M | +126.1% |
| Q1 FY2022 | Mar 31, 2022 | $52.94M | +157.6% |
| Q4 FY2021 | Dec 31, 2021 | $42.58M | +144.3% |
| Q3 FY2021 | Sep 30, 2021 | $27.51M | +67.0% |
| Q2 FY2021 | Jun 30, 2021 | $22.27M | +48.3% |
| Q1 FY2021 | Mar 31, 2021 | $20.55M | +34.7% |
| Q4 FY2020 | Dec 31, 2020 | $17.43M | +22.1% |
| Q3 FY2020 | Sep 30, 2020 | $16.47M | +10.1% |
| Q2 FY2020 | Jun 30, 2020 | $15.01M | +0.7% |
| Q1 FY2020 | Mar 31, 2020 | $15.25M | -1.5% |
| Q4 FY2019 | Dec 31, 2019 | $14.27M | -12.2% |
| Q3 FY2019 | Sep 30, 2019 | $14.96M | +4.2% |
| Q2 FY2019 | Jun 30, 2019 | $14.91M | -4.8% |
| Q1 FY2019 | Mar 31, 2019 | $15.49M | -5.1% |
| Q4 FY2018 | Dec 31, 2018 | $16.26M | +4.1% |
| Q3 FY2018 | Sep 30, 2018 | $14.36M | -9.4% |
| Q2 FY2018 | Jun 30, 2018 | $15.66M | -7.2% |
| Q1 FY2018 | Mar 31, 2018 | $16.31M | -3.9% |
| Q4 FY2017 | Dec 31, 2017 | $15.63M | -3.9% |
| Q3 FY2017 | Sep 30, 2017 | $15.84M | – |
| Q2 FY2017 | Jun 30, 2017 | $16.88M | – |
| Q1 FY2017 | Mar 31, 2017 | $16.97M | – |
| Q4 FY2016 | Dec 31, 2016 | $16.26M | – |
See a number that looks wrong?